SCHEMBL24136183

SCHEMBL24136183

Cc1ccc(F)c2c1cc(Cl)n2C

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPM5 Q9NZQ8 1/20 0.35
HSD11B1 P28845 3/20 0.33
CYP3A4 P08684 1/20 0.32
MAPT P10636 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
PARP15 Q460N3 1/20 0.32
PARP10 Q53GL7 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
ALDH1A1 P00352 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
PTGS2 P35354 3/20 0.30
JAK2 O60674 1/20 0.30
BTK Q06187 1/20 0.30
CYP1A2 P05177 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22434776 0.85 CYP11B1 (0.36) TRPM5HSD11B1MAPTALDH1A1KDM4E
SCHEMBL22434864 0.80 PARP15 (0.33) MAPTPARP15PARP10TNKS2PARP2
SCHEMBL22434659 0.79 L3MBTL1 (0.41) HSD11B1MAPTALDH1A1PTGS2
SCHEMBL22434657 0.73 AR (0.40) ALDH1A1JAK2
SCHEMBL22434866 0.72 HSD11B1 (0.36) HSD11B1MAPTALDH1A1RAPGEF4KDM4E
SCHEMBL22434755 0.69 CASP1 (0.33) JAK2BTK
SCHEMBL24136193 0.69 HRH4 (0.33) PARP15PARP10TNKS2PARP2HRH4
SCHEMBL24496668 0.68 RORC (0.32)
SCHEMBL14981460 0.68 F2RL1 (0.36) PARP15PARP10TNKS2PARP2KDM4E
SCHEMBL22434752 0.67 ALKBH5 (0.36) MAPTKDM4EHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 TRPM5 750/4885HSD11B1 305/4885CYP3A4 154/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 TRPM5 750/4885HSD11B1 305/4885CYP3A4 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.